Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD
| Autor: | Władysław Pierzchała, Gabriele Nicolini, Jorg Kampschulte, Mária Szilasi, Jørgen Vestbo, Daniele Guastalla, Claudio Terzano, Dave Singh, Abdullah Sayiner, Massimo Corradi, Eddi Bindi |
|---|---|
| Přispěvatelé: | Ege Üniversitesi |
| Jazyk: | angličtina |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Androstadienes/therapeutic use Klinikai orvostudományok Fluticasone propionate Beclomethasone/administration & dosage law.invention Fluticasone-Salmeterol Combination Pulmonary Disease Chronic Obstructive Randomized controlled trial Double-Blind Method law Bronchodilator Agents/administration & dosage Internal medicine Ethanolamines/administration & dosage Formoterol Fumarate Medicine Humans Albuterol Glucocorticoids Fluticasone-Salmeterol Drug Combination COPD business.industry Beclomethasone Glucocorticoids/administration & dosage Orvostudományok Middle Aged respiratory system medicine.disease Pulmonary Disease Chronic Obstructive/drug therapy Bronchodilator Agents respiratory tract diseases Androstadienes Drug Combinations Ethanolamines Albuterol/analogs & derivatives Female Formoterol Salmeterol business medicine.drug Research Article |
| Zdroj: | BMC Pulmonary Medicine Singh, D, Nicolini, G, Bindi, E, Corradi, M, Guastalla, D, Kampschulte, J, Pierzchala, W, Sayiner, A, Szilasi, M, Terzano, C, Vestbo, J & TherapeUtic, F F U 2014, ' Extrafine Beclomethasone/formoterol compared to Fluticasone/salmeterol Combination Therapy in COPD ', B M C Pulmonary Medicine, vol. 14, 43 . https://doi.org/10.1186/1471-2466-14-43 |
| ISSN: | 1471-2466 |
| DOI: | 10.1186/1471-2466-14-43 |
| Popis: | WOS: 000335358300001 PubMed ID: 24621109 Background: The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination in COPD patients. Methods: The trial was a 12-week multicentre, randomised, double-blind, double dummy study; 419 patients with moderate/severe COPD were randomised to BDP/FF 200/12 mu g or FP/S 500/50 mu g twice daily. The primary objective was to demonstrate the equivalence between treatments in terms of Transition Dyspnoea Index (TDI) score and the superiority of BDP/FF in terms of change from pre- dose in the first 30 minutes in forced expiratory volume in the first second (FEV1). Secondary endpoints included lung function, symptom scores, symptom-free days and use of rescue medication, St. George's Respiratory Questionnaire, six minute walking test and COPD exacerbations. Results: BDP/FF was equivalent to FP/S in terms of TDI score and superior in terms of FEV1 change from pre- dose (p < 0.001). There were no significant differences between treatments in secondary outcome measures, confirming overall comparability in terms of efficacy and tolerability. Moreover, a clinically relevant improvement (> 4 units) in SGRQ was detected in the BDP/FF group only. Conclusion: BDP/FF extrafine combination provides COPD patients with an equivalent improvement of dyspnoea and a faster bronchodilation in comparison to FP/S. Chiesi Farmaceutici S.p.A., Parma, Italy This study was funded by Chiesi Farmaceutici S.p.A., Parma, Italy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|